Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Prüfung der Verwendung von AMG 510 (Sotorasib) und Panitumumab als zielgerichtete Behandlung von KRAS G12C-mutierten soliden Tumoren (eine ComboMATCH-Behandlungsstudie)

21. Oktober 2026 aktualisiert von: National Cancer Institute (NCI)

Eine randomisierte Phase-II-Studie mit AMG 510 (Sotorasib) mit oder ohne Panitumumab bei fortgeschrittenen soliden Tumoren: Eine ComboMATCH-Behandlungsstudie

This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 (sotorasib) alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except colorectal carcinoma [CRC] and non-small cell lung carcinoma [NSCLC]) as measured by progression free survival (Cohort 1).

II. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by response rate (Cohort 2).

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except CRC and NSCLC) as measured by response rate, disease control rate, and overall survival (Cohort 1).

II, To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by disease control rate, progression free survival (PFS), and overall survival (Cohort 2).

III. To further evaluate the safety and tolerability of the combination of AMG 510 (sotorasib) and panitumumab.

IV. To collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor-derived deoxyribonucleic acid (DNA) (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.

CORRELATIVE EXPLORATORY OBJECTIVES:

I. To investigate the impact of concomitant mutations on the clinical benefit. II. To evaluate if changes in circulating tumor DNA (ctDNA) over time correlate with response to treatment.

III. To evaluate the relative mutant allele fraction of KRAS mutation as a predictor of clinical benefit.

IV. To evaluate if ERK 1/2 and PI3K pathway activation correlate with response and/or resistance.

OUTLINE: Patients are assigned to 1 of 2 cohorts.

COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B.

ARM A: Patients receive sotorasib orally (PO) once daily (QD) on days 1-28 and panitumumab intravenously (IV) on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and computed tomography (CT) or magnetic resonance imaging (MRI) on study.

ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.

COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.

ARM C: Patients receive combination therapy as in Arm A.

After completion of study treatment, patients are followed up at 30 days and then every 3-6 months for up to 36 months.

Studientyp

Interventionell

Einschreibung (Geschätzt)

105

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35233
        • University of Alabama at Birmingham Cancer Center
      • Mobile, Alabama, Vereinigte Staaten, 36688
        • University of South Alabama Mitchell Cancer Institute
    • California
      • Los Angeles, California, Vereinigte Staaten, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, Vereinigte Staaten, 90025
        • The Angeles Clinic and Research Institute - West Los Angeles Office
      • Palo Alto, California, Vereinigte Staaten, 94304
        • VA Palo Alto Health Care System
    • Florida
      • Aventura, Florida, Vereinigte Staaten, 33180
        • UM Sylvester Comprehensive Cancer Center at Aventura
      • Coral Gables, Florida, Vereinigte Staaten, 33146
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
      • Coral Springs, Florida, Vereinigte Staaten, 33065
        • UM Sylvester Comprehensive Cancer Center at Coral Springs
      • Deerfield Beach, Florida, Vereinigte Staaten, 33442
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
      • Hollywood, Florida, Vereinigte Staaten, 33021
        • UM Sylvester Comprehensive Cancer Center at Hollywood
      • Jacksonville, Florida, Vereinigte Staaten, 32224-9980
        • Mayo Clinic in Florida
      • Miami, Florida, Vereinigte Staaten, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Miami, Florida, Vereinigte Staaten, 33176
        • UM Sylvester Comprehensive Cancer Center at Kendall
      • Plantation, Florida, Vereinigte Staaten, 33324
        • UM Sylvester Comprehensive Cancer Center at Plantation
    • Idaho
      • Boise, Idaho, Vereinigte Staaten, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Boise, Idaho, Vereinigte Staaten, 83712
        • Saint Luke's Cancer Institute - Boise
      • Caldwell, Idaho, Vereinigte Staaten, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
        • Kootenai Health - Coeur d'Alene
      • Fruitland, Idaho, Vereinigte Staaten, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Vereinigte Staaten, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Vereinigte Staaten, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Vereinigte Staaten, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Vereinigte Staaten, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Vereinigte Staaten, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
    • Illinois
      • Barrington, Illinois, Vereinigte Staaten, 60010
        • Advocate Good Shepherd Hospital
      • Chicago, Illinois, Vereinigte Staaten, 60612
        • University of Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60612
        • John H Stroger Jr Hospital of Cook County
      • Chicago, Illinois, Vereinigte Staaten, 60657
        • Advocate Illinois Masonic Medical Center
      • Crystal Lake, Illinois, Vereinigte Staaten, 60014
        • AMG Crystal Lake - Oncology
      • Danville, Illinois, Vereinigte Staaten, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, Vereinigte Staaten, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Vereinigte Staaten, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Downers Grove, Illinois, Vereinigte Staaten, 60515
        • Advocate Good Samaritan Hospital
      • Effingham, Illinois, Vereinigte Staaten, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, Vereinigte Staaten, 62401
        • Carle Physician Group-Effingham
      • Elgin, Illinois, Vereinigte Staaten, 60123
        • Advocate Sherman Hospital
      • Hazel Crest, Illinois, Vereinigte Staaten, 60429
        • Advocate South Suburban Hospital
      • Libertyville, Illinois, Vereinigte Staaten, 60048
        • Condell Memorial Hospital
      • Libertyville, Illinois, Vereinigte Staaten, 60048
        • AMG Libertyville - Oncology
      • Mattoon, Illinois, Vereinigte Staaten, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Maywood, Illinois, Vereinigte Staaten, 60153
        • Loyola University Medical Center
      • Normal, Illinois, Vereinigte Staaten, 61761
        • Carle Cancer Institute Normal
      • Normal, Illinois, Vereinigte Staaten, 61761
        • Carle BroMenn Medical Center
      • O'Fallon, Illinois, Vereinigte Staaten, 62269
        • Cancer Care Center of O'Fallon
      • Oak Lawn, Illinois, Vereinigte Staaten, 60453-2699
        • Advocate Christ Medical Center
      • Oak Lawn, Illinois, Vereinigte Staaten, 60453
        • Advocate Outpatient Center - Oak Lawn
      • Palos Heights, Illinois, Vereinigte Staaten, 60463
        • Advocate High Tech Medical Park
      • Park Ridge, Illinois, Vereinigte Staaten, 60068
        • Advocate Lutheran General Hospital
      • Shiloh, Illinois, Vereinigte Staaten, 62269
        • Memorial Hospital East
      • Springfield, Illinois, Vereinigte Staaten, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Vereinigte Staaten, 62702
        • Springfield Clinic
      • Springfield, Illinois, Vereinigte Staaten, 62781
        • Springfield Memorial Hospital
      • Urbana, Illinois, Vereinigte Staaten, 61801
        • Carle Cancer Center
    • Iowa
      • Ankeny, Iowa, Vereinigte Staaten, 50023
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Des Moines, Iowa, Vereinigte Staaten, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, Vereinigte Staaten, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Waukee, Iowa, Vereinigte Staaten, 50263
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
    • Kentucky
      • Lexington, Kentucky, Vereinigte Staaten, 40536
        • University of Kentucky/Markey Cancer Center
    • Maine
      • Brewer, Maine, Vereinigte Staaten, 04412
        • Lafayette Family Cancer Center-EMMC
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21201
        • University of Maryland/Greenebaum Cancer Center
      • Bethesda, Maryland, Vereinigte Staaten, 20892
        • National Institutes of Health Clinical Center
      • Bethesda, Maryland, Vereinigte Staaten, 20889-5600
        • Walter Reed National Military Medical Center
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Brighton, Michigan, Vereinigte Staaten, 48114
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Brighton, Michigan, Vereinigte Staaten, 48114
        • Trinity Health Medical Center - Brighton
      • Canton, Michigan, Vereinigte Staaten, 48188
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Canton, Michigan, Vereinigte Staaten, 48188
        • Trinity Health Medical Center - Canton
      • Chelsea, Michigan, Vereinigte Staaten, 48118
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Chelsea, Michigan, Vereinigte Staaten, 48118
        • Chelsea Hospital
      • Dearborn, Michigan, Vereinigte Staaten, 48124
        • Corewell Health Dearborn Hospital
      • Farmington Hills, Michigan, Vereinigte Staaten, 48336
        • Corewell Health Farmington Hills Hospital
      • Flint, Michigan, Vereinigte Staaten, 48503
        • Hurley Medical Center
      • Flint, Michigan, Vereinigte Staaten, 48503
        • Genesee Hematology Oncology PC
      • Flint, Michigan, Vereinigte Staaten, 48503
        • Genesys Hurley Cancer Institute
      • Flint, Michigan, Vereinigte Staaten, 48503
        • Cancer Hematology Centers - Flint
      • Lansing, Michigan, Vereinigte Staaten, 48912
        • University of Michigan Health - Sparrow Lansing
      • Livonia, Michigan, Vereinigte Staaten, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Pontiac, Michigan, Vereinigte Staaten, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Royal Oak, Michigan, Vereinigte Staaten, 48073
        • Corewell Health William Beaumont University Hospital
      • Royal Oak, Michigan, Vereinigte Staaten, 48073
        • Corewell Health Children's
      • Saginaw, Michigan, Vereinigte Staaten, 48604
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, Vereinigte Staaten, 48601
        • MyMichigan Medical Center Saginaw
      • Tawas City, Michigan, Vereinigte Staaten, 48764
        • MyMichigan Medical Center Tawas
      • Troy, Michigan, Vereinigte Staaten, 48085
        • Corewell Health Beaumont Troy Hospital
      • West Branch, Michigan, Vereinigte Staaten, 48661
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Ypsilanti, Michigan, Vereinigte Staaten, 48197
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
      • Ypsilanti, Michigan, Vereinigte Staaten, 48106
        • Huron Gastroenterology PC
    • Minnesota
      • Deer River, Minnesota, Vereinigte Staaten, 56636
        • Essentia Health - Deer River Clinic
      • Duluth, Minnesota, Vereinigte Staaten, 55805
        • Essentia Health Cancer Center
      • Hibbing, Minnesota, Vereinigte Staaten, 55746
        • Essentia Health Hibbing Clinic
      • Rochester, Minnesota, Vereinigte Staaten, 55905
        • Mayo Clinic in Rochester
      • Sandstone, Minnesota, Vereinigte Staaten, 55072
        • Essentia Health Sandstone
      • Virginia, Minnesota, Vereinigte Staaten, 55792
        • Essentia Health Virginia Clinic
    • Missouri
      • Cape Girardeau, Missouri, Vereinigte Staaten, 63703
        • Saint Francis Medical Center
      • City of Saint Peters, Missouri, Vereinigte Staaten, 63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, Vereinigte Staaten, 63141
        • Siteman Cancer Center at West County Hospital
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Vereinigte Staaten, 63129
        • Siteman Cancer Center-South County
      • St Louis, Missouri, Vereinigte Staaten, 63136
        • Siteman Cancer Center at Christian Hospital
    • Montana
      • Anaconda, Montana, Vereinigte Staaten, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Vereinigte Staaten, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, Vereinigte Staaten, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, Vereinigte Staaten, 59405
        • Benefis Sletten Cancer Institute
      • Kalispell, Montana, Vereinigte Staaten, 59901
        • Logan Health Medical Center
      • Missoula, Montana, Vereinigte Staaten, 59804
        • Community Medical Center
    • Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89102
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, Vereinigte Staaten, 89135
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Las Vegas, Nevada, Vereinigte Staaten, 89183
        • OptumCare Cancer Care at Fort Apache
    • New Jersey
      • New Brunswick, New Jersey, Vereinigte Staaten, 08903
        • Rutgers Cancer Institute of New Jersey
    • New Mexico
      • Albuquerque, New Mexico, Vereinigte Staaten, 87106
        • University of New Mexico Cancer Center
    • New York
      • Buffalo, New York, Vereinigte Staaten, 14263
        • Roswell Park Cancer Institute
      • Mineola, New York, Vereinigte Staaten, 11501
        • NYU Langone Hospital - Long Island
      • New York, New York, Vereinigte Staaten, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    • Ohio
      • Columbus, Ohio, Vereinigte Staaten, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Vereinigte Staaten, 43214
        • Columbus Oncology and Hematology Associates Inc
      • Columbus, Ohio, Vereinigte Staaten, 43228
        • Doctors Hospital
      • Columbus, Ohio, Vereinigte Staaten, 43215
        • Grant Medical Center
      • Dayton, Ohio, Vereinigte Staaten, 45415
        • Dayton Physician LLC - Englewood
      • Delaware, Ohio, Vereinigte Staaten, 43015
        • Delaware Health Center-Grady Cancer Center
      • Delaware, Ohio, Vereinigte Staaten, 43015
        • Grady Memorial Hospital
      • Dublin, Ohio, Vereinigte Staaten, 43016
        • Dublin Methodist Hospital
      • Dublin, Ohio, Vereinigte Staaten, 43016
        • Columbus Oncology and Hematology Associates
      • Kettering, Ohio, Vereinigte Staaten, 45429
        • Kettering Medical Center
      • Mansfield, Ohio, Vereinigte Staaten, 44903
        • OhioHealth Mansfield Hospital
      • Marion, Ohio, Vereinigte Staaten, 43302
        • OhioHealth Marion General Hospital
    • Oklahoma
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Ontario, Oregon, Vereinigte Staaten, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
      • Portland, Oregon, Vereinigte Staaten, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Vereinigte Staaten, 97225
        • Providence Saint Vincent Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
        • Thomas Jefferson University Hospital
      • Willow Grove, Pennsylvania, Vereinigte Staaten, 19090
        • Asplundh Cancer Pavilion
    • South Carolina
      • Boiling Springs, South Carolina, Vereinigte Staaten, 29316
        • Prisma Health Cancer Institute - Spartanburg
      • Easley, South Carolina, Vereinigte Staaten, 29640
        • Prisma Health Cancer Institute - Easley
      • Greenville, South Carolina, Vereinigte Staaten, 29605
        • Prisma Health Cancer Institute - Faris
      • Greenville, South Carolina, Vereinigte Staaten, 29615
        • Prisma Health Cancer Institute - Eastside
      • Greenville, South Carolina, Vereinigte Staaten, 29605
        • Prisma Health Cancer Institute - Butternut
      • Greer, South Carolina, Vereinigte Staaten, 29650
        • Prisma Health Cancer Institute - Greer
      • Seneca, South Carolina, Vereinigte Staaten, 29672
        • Prisma Health Cancer Institute - Seneca
    • South Dakota
      • Rapid City, South Dakota, Vereinigte Staaten, 57701
        • Rapid City Regional Hospital
    • Tennessee
      • Bristol, Tennessee, Vereinigte Staaten, 37620
        • Bristol Regional Medical Center
      • Johnson City, Tennessee, Vereinigte Staaten, 37604
        • Regional Cancer Center at Johnson City Medical Center
      • Kingsport, Tennessee, Vereinigte Staaten, 37660
        • Ballad Health Cancer Care - Kingsport
      • Kingsport, Tennessee, Vereinigte Staaten, 37660
        • Wellmont Holston Valley Hospital and Medical Center
      • Nashville, Tennessee, Vereinigte Staaten, 37232
        • Vanderbilt University/Ingram Cancer Center
    • Texas
      • Temple, Texas, Vereinigte Staaten, 76508
        • Scott and White Memorial Hospital
    • Virginia
      • Bristol, Virginia, Vereinigte Staaten, 24201
        • Ballad Health Cancer Care - Bristol
      • Charlottesville, Virginia, Vereinigte Staaten, 22908
        • University of Virginia Cancer Center
      • Richmond, Virginia, Vereinigte Staaten, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Vereinigte Staaten, 23298
        • VCU Massey Comprehensive Cancer Center
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98122
        • Swedish Medical Center-First Hill
    • West Virginia
      • Charleston, West Virginia, Vereinigte Staaten, 25304
        • Vandalia Health/CAMC Institute for Academic Medicine
    • Wisconsin
      • Appleton, Wisconsin, Vereinigte Staaten, 54911
        • ThedaCare Regional Cancer Center
      • Ashland, Wisconsin, Vereinigte Staaten, 54806
        • Duluth Clinic Ashland
      • Berlin, Wisconsin, Vereinigte Staaten, 54923
        • ThedaCare Cancer Care - Berlin
      • Burlington, Wisconsin, Vereinigte Staaten, 53105
        • Aurora Cancer Care-Southern Lakes VLCC
      • Cudahy, Wisconsin, Vereinigte Staaten, 53110
        • Aurora Saint Luke's South Shore
      • Germantown, Wisconsin, Vereinigte Staaten, 53022
        • Aurora Health Care Germantown Health Center
      • Grafton, Wisconsin, Vereinigte Staaten, 53024
        • Aurora Cancer Care-Grafton
      • Green Bay, Wisconsin, Vereinigte Staaten, 54311
        • Aurora BayCare Medical Center
      • Janesville, Wisconsin, Vereinigte Staaten, 53548
        • Mercyhealth Hospital and Cancer Center - Janesville
      • Kenosha, Wisconsin, Vereinigte Staaten, 53142
        • Aurora Cancer Care-Kenosha South
      • La Crosse, Wisconsin, Vereinigte Staaten, 54601
        • Gundersen Lutheran Medical Center
      • Madison, Wisconsin, Vereinigte Staaten, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Madison, Wisconsin, Vereinigte Staaten, 53718
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
      • Marinette, Wisconsin, Vereinigte Staaten, 54143
        • Aurora Bay Area Medical Group-Marinette
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53209
        • Aurora Cancer Care-Milwaukee
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53215
        • Aurora Saint Luke's Medical Center
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53233
        • Aurora Sinai Medical Center
      • Neenah, Wisconsin, Vereinigte Staaten, 54956
        • ThedaCare Regional Medical Center - Neenah
      • New London, Wisconsin, Vereinigte Staaten, 54961
        • ThedaCare Cancer Care - New London
      • Oshkosh, Wisconsin, Vereinigte Staaten, 54904
        • Vince Lombardi Cancer Clinic - Oshkosh
      • Oshkosh, Wisconsin, Vereinigte Staaten, 54904
        • ThedaCare Cancer Care - Oshkosh
      • Racine, Wisconsin, Vereinigte Staaten, 53406
        • Aurora Cancer Care-Racine
      • Shawano, Wisconsin, Vereinigte Staaten, 54166
        • ThedaCare Cancer Care - Shawano
      • Sheboygan, Wisconsin, Vereinigte Staaten, 53081
        • Vince Lombardi Cancer Clinic-Sheboygan
      • Summit, Wisconsin, Vereinigte Staaten, 53066
        • Aurora Medical Center in Summit
      • Two Rivers, Wisconsin, Vereinigte Staaten, 54241
        • Vince Lombardi Cancer Clinic-Two Rivers
      • Waupaca, Wisconsin, Vereinigte Staaten, 54981
        • ThedaCare Cancer Care - Waupaca
      • Wauwatosa, Wisconsin, Vereinigte Staaten, 53226
        • Aurora Cancer Care-Milwaukee West
      • West Allis, Wisconsin, Vereinigte Staaten, 53227
        • Aurora West Allis Medical Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable mutation as defined in EAY191

  • Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration/randomization to the EAY191-E5 study

  • Patient must be >= 18 years of age

  • Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment

  • Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191-E5)

    • NOTE: The current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website: www.ctsu.org (final URL pending)
    • NOTE: Novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH registration protocol
  • Patient must have cytologically/histologically confirmed advanced/metastatic solid tumor

  • Patient must have progressed on at least one line of standard of care therapy in the advanced/metastatic setting

    • NOTE: Patients who have progressed on a prior human epidermal growth factor receptor (EGFR) inhibitor will meet this criterion
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 (or Karnofsky performance status >= 60%)

  • Patient must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) documented by imaging obtained within 28 days prior to registration/randomization

  • Patient must not have any serious active infection within 4 weeks prior to EAY191-E5 registration/randomization (e.g., requiring hospitalization and/or intravenous [IV] antibiotics) or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible

  • Patient must have the ability to retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption

  • Patient must not have any history of or current evidence of non-infectious interstitial lung disease (ILD)/pneumonitis

  • Patient must not have a history of allergic reactions attributed to either of the study agents or to agents of similar chemical or biologic composition

  • Patient must have completed full treatment cycle 21 days prior to EAY191-E5 registration/randomization if they have received prior chemotherapy, biological cancer therapy, radiation therapy or an investigational agent/device. Patients must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia)

  • Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration/randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for at least 6 months after the last dose of protocol treatment. Patients must not breastfeed while receiving protocol treatment and for one week (7 days) after the last dose of AMG 510 (sotorasib) and 2 months after the last dose of panitumumab

  • Patients must not have neuropathy ≥ grade 2 within 14 days prior to registration/randomization

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression

  • Human immunodeficiency virus (HIV)-infected patients no effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with known history or current symptoms of cardiac history, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trail, patients should be class 2B or better

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 28 days prior to protocol registration/randomization)

  • Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase ([SGPT]) < 3 x institutional upper limit of normal (obtained ≤ 28 days prior to protocol registration/randomization)

  • Creatinine =< 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 mg/dL as per Cockcroft-Gault (obtained ≤ 28 days prior to protocol registration/randomization)

  • COHORT I: Patient must not have colorectal cancer or non-small cell lung cancer

  • COHORT I: Patient must not have been previously treated with a KRAS G12C inhibitor

  • COHORT II: Patient must have progressed after treatment at the recommended phase II dose (RP2D) of any KRAS G12C inhibitor

    • NOTE: Patients on cohort 1 who experience progression on Regimen 2 (AMG 510 [sotorasib] alone) may be eligible to enroll on cohort 2 and receive combination treatment with panitumumab and AMG 510 (sotorasib). Patients must meet performance status requirements and laboratory values as above and must be begin treatment within 7 days of enrollment. Migration to cohort 2 must take place within 6 months of progression, with no intervening anti-cancer therapy given.
    • NOTE: Cohort migration following disease progression is dependent on a slot being available. MATCHBox makes the new treatment assignment following initiation of a step 2 registration for this treatment trial
  • COHORT II: Patient must not have been previously treated with a KRAS G12C inhibitor in combination with an EGFR inhibitor

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Cohort I Arm A (sotorasib, panitumumab)

Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.

Undergo MRI

Andere Namen:
  • MRT
  • Magnetresonanz
  • Magnetresonanztomographie-Scan
  • Medizinische Bildgebung, Magnetresonanz / Kernspinresonanz
  • HERR
  • MR-Bildgebung
  • MRT-Untersuchung
  • NMR-Bildgebung
  • NMRI
  • Kernspinresonanztomographie
  • Magnetresonanztomographie (MRT)
  • sMRT
  • Magnetresonanztomographie (Verfahren)
  • MRTs
  • Strukturelle MRT

Undergo collection of blood

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme
  • Beispielsammlung

Undergo CT scan

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)
  • Computertomographie (CT)-Scan
  • Diagnosekatze Scan
  • Diagnose -Katzen -Scan -Service -Typ

Undergo tumor biopsy

Andere Namen:
  • Bx
  • BIOPSY_TYPE
  • Biopsie

Given IV

Andere Namen:
  • ABX-EGF
  • Monoklonaler ABX-EGF-Antikörper
  • ABX-EGF, Klon E7.6.3
  • MoAb ABX-EGF
  • Monoklonaler Antikörper ABX-EGF
  • Vectibix
  • E7.6.3
  • Menschlicher monoklonaler IgG2K-Antikörper
  • MoAb E7.6.3
  • Monoklonaler Antikörper E7.6.3

Given PO

Andere Namen:
  • AMG 510
  • Lumakras
  • AMG-510
  • AMG510
  • Lumykras
Aktiver Komparator: Cohort I Arm B (sotorasib)

Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.

Undergo MRI

Andere Namen:
  • MRT
  • Magnetresonanz
  • Magnetresonanztomographie-Scan
  • Medizinische Bildgebung, Magnetresonanz / Kernspinresonanz
  • HERR
  • MR-Bildgebung
  • MRT-Untersuchung
  • NMR-Bildgebung
  • NMRI
  • Kernspinresonanztomographie
  • Magnetresonanztomographie (MRT)
  • sMRT
  • Magnetresonanztomographie (Verfahren)
  • MRTs
  • Strukturelle MRT

Undergo collection of blood

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme
  • Beispielsammlung

Undergo CT scan

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)
  • Computertomographie (CT)-Scan
  • Diagnosekatze Scan
  • Diagnose -Katzen -Scan -Service -Typ

Undergo tumor biopsy

Andere Namen:
  • Bx
  • BIOPSY_TYPE
  • Biopsie

Given PO

Andere Namen:
  • AMG 510
  • Lumakras
  • AMG-510
  • AMG510
  • Lumykras
Experimental: Cohort II (sotorasib, panitumumab)

Patients receive combination therapy as in Arm A.

Undergo MRI

Andere Namen:
  • MRT
  • Magnetresonanz
  • Magnetresonanztomographie-Scan
  • Medizinische Bildgebung, Magnetresonanz / Kernspinresonanz
  • HERR
  • MR-Bildgebung
  • MRT-Untersuchung
  • NMR-Bildgebung
  • NMRI
  • Kernspinresonanztomographie
  • Magnetresonanztomographie (MRT)
  • sMRT
  • Magnetresonanztomographie (Verfahren)
  • MRTs
  • Strukturelle MRT

Undergo collection of blood

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme
  • Beispielsammlung

Undergo CT scan

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)
  • Computertomographie (CT)-Scan
  • Diagnosekatze Scan
  • Diagnose -Katzen -Scan -Service -Typ

Undergo tumor biopsy

Andere Namen:
  • Bx
  • BIOPSY_TYPE
  • Biopsie

Given IV

Andere Namen:
  • ABX-EGF
  • Monoklonaler ABX-EGF-Antikörper
  • ABX-EGF, Klon E7.6.3
  • MoAb ABX-EGF
  • Monoklonaler Antikörper ABX-EGF
  • Vectibix
  • E7.6.3
  • Menschlicher monoklonaler IgG2K-Antikörper
  • MoAb E7.6.3
  • Monoklonaler Antikörper E7.6.3

Given PO

Andere Namen:
  • AMG 510
  • Lumakras
  • AMG-510
  • AMG510
  • Lumykras

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression-free survival (PFS) (Cohort I)
Zeitfenster: From registration to documented disease progression or death from any cause, assessed up to 3 years

PFS will be compared between the arms using a one-sided log rank test with 10% type I error. Cox's proportional hazards model will be used to estimate the PFS hazard ratio between the treatment arms and a two-sided 80% confidence interval will be reported (to correspond to the one-sided 10% type I error). Confidence intervals on most other quantities will use the two-sided 90% level.

From registration to documented disease progression or death from any cause, assessed up to 3 years
Best objective response (Cohort II)
Zeitfenster: From the start of the treatment until disease progression/recurrence, assessed up to 3 years

Will be evaluated using the criteria defined by Response Evaluation Criteria in Solid Tumors) version 1.1 for patients with solid tumors.

From the start of the treatment until disease progression/recurrence, assessed up to 3 years
Overall response rate (ORR) (Cohort II)
Zeitfenster: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years

The exact 90% confidence interval on the ORR (determined using the method of Atkinson and Brown) will be reported. If the number of analyzable cases is less than 35, a 5% one-sided test will still be used.

From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall survival (OS) (Cohort I)
Zeitfenster: Up to 3 years

OS distributions by treatment will be estimated and 90% confidence intervals on estimated rates at 6 and 12 months will be reported. The OS hazard ratio will be estimated using Cox proportional hazards model and a 90% confidence interval reported.

Up to 3 years
ORR (Cohort I)
Zeitfenster: Up to 3 years

Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed.

Up to 3 years
Disease control rates (Cohort I)
Zeitfenster: From the start of the treatment until the criteria for progression are met, assessed up to 3 years

Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed.

From the start of the treatment until the criteria for progression are met, assessed up to 3 years
PFS (Cohort II)
Zeitfenster: At 6 and 12 months, assessed up to 3 years

Will be estimated and 90% confidence intervals on estimated rates will be reported.

At 6 and 12 months, assessed up to 3 years
OS (Cohort II)
Zeitfenster: At 6 and 12 months, assessed up to 3 years

Will be estimated and 90% confidence intervals on estimated rates will be reported.

At 6 and 12 months, assessed up to 3 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Kristen R Spencer, ECOG-ACRIN Cancer Research Group

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. August 2024

Primärer Abschluss (Geschätzt)

31. Dezember 2028

Studienabschluss (Geschätzt)

31. Dezember 2028

Studienanmeldedaten

Zuerst eingereicht

2. Dezember 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Dezember 2022

Zuerst gepostet (Tatsächlich)

6. Dezember 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NCI-2022-09876
  • U10CA180820 (US NIH Stipendium/Vertrag)
  • NCI-2022-09876 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
  • EAY191-E5 (Andere Kennung: CTEP)
  • EAY191-E5 (Andere Kennung: ECOG-ACRIN Cancer Research Group)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .